The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.

On Tuesday, the U.S. Federal Trade Commission (FTC) presented evidence that UnitedHealth Group’s OptumRx, along with its two main competitors, Express Scripts and CVS Caremark Rx, inflated the ...

Here is a hard truth for those of us who are care providers: Americans are unsatisfied with the country's healthcare system.

the U.S. Federal Trade Commission said on Tuesday. From 2017 to 2022, the companies — UnitedHealth Group's UNH.N Optum, CVS Health's CVS.N CVS Caremark and Cigna's CI.N Express Scripts ...

Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's ...

and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

The updated tally extends the scope beyond what was previously described by company Chief Executive Andrew Witty.